Liu, S. & Kurzrock, R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat. Rev. 40, 883–891 (2014).

CAS  PubMed  Google Scholar 

Corsello, S. M. et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235–248 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Douillard, J.-Y. et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 110, 55–62 (2014).

CAS  PubMed  Google Scholar 

Nan, X., Xie, C., Yu, X. & Liu, J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 8, 75712–75726 (2017).

PubMed  PubMed Central  Google Scholar 

Kazandjian, D. et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin. Cancer Res. 22, 1307–1312 (2016).

CAS  PubMed  Google Scholar 

Khozin, S. et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19, 774–779 (2014).

CAS  PubMed  PubMed Central  Google Scholar 

Khozin, S. et al. Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer. Clin. Cancer Res. 23, 2131–2135 (2017).

CAS  PubMed  Google Scholar 

Hazarika, M. et al. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin. Cancer Res. 23, 3484–3488 (2017).

CAS  PubMed  Google Scholar 

Kim, G. et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin. Cancer Res. 20, 4994–5000 (2014).

CAS  PubMed  Google Scholar 

Odogwu, L. et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist 23, 740–745 (2018).

CAS  PubMed  PubMed Central  Google Scholar 

Narayan, P. et al. FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin. Cancer Res. 27, 1842–1849 (2021).

CAS  PubMed  Google Scholar 

Ison, G. et al. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy. Clin. Cancer Res. 24, 4066–4071 (2018).

CAS  PubMed  Google Scholar 

Anscher, M. S. et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-mutated metastatic castrate-resistant prostate cancer. Oncologist 26, 139–146 (2021).

CAS  PubMed  Google Scholar 

Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Kohsaka, S. et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci. Transl. Med. 9, eaan6566 (2017).

PubMed  Google Scholar 

Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).

CAS  PubMed  Google Scholar 

Zhang, X.-T. et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. 16, 1334–1342 (2005).

PubMed  Google Scholar 

Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

CAS  PubMed  PubMed Central  Google Scholar 

Janku, F. et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol. Cancer Ther. 10, 558–565 (2011).

CAS  PubMed  PubMed Central  Google Scholar 

Janku, F. et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30, 777–782 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Rydzewski, N. R. et al. Predicting cancer drug TARGETS - treatment response generalized elastic-neT signatures. NPJ Genom. Med. 6, 76 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).

CAS  PubMed  PubMed Central  Google Scholar 

Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Polano, M. et al. A pan-cancer approach to predict responsiveness to immune checkpoint inhibitors by machine learning. Cancers 11, E1562 (2019).

PubMed  Google Scholar 

Reinhold, W. C. et al. Using drug response data to identify molecular effectors, and molecular ‘omic’ data to identify candidate drugs in cancer. Hum. Genet 134, 3–11 (2015).

CAS  PubMed  Google Scholar 

Wang, X., Sun, Z., Zimmermann, M. T., Bugrim, A. & Kocher, J.-P. Predict drug sensitivity of cancer cells with pathway activity inference. BMC Med Genomics 12, 15 (2019).

PubMed  PubMed Central  Google Scholar 

Dhruba, S. R., Rahman, R., Matlock, K., Ghosh, S. & Pal, R. Application of transfer learning for cancer drug sensitivity prediction. BMC Bioinforma. 19, 497 (2018).

CAS  Google Scholar 

Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34, 3907–3914 (2018).

CAS  PubMed  Google Scholar 

Wang, L., Li, X., Zhang, L. & Gao, Q. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer 17, 513 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Pleasance, E. et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nat. Cancer 1, 452–468 (2020).

CAS  PubMed  Google Scholar 

Sharifi-Noghabi, H., Peng, S., Zolotareva, O., Collins, C. C. & Ester, M. AITL: adversarial inductive transfer learning with input and output space adaptation for pharmacogenomics. Bioinformatics 36, i380–i388 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C. & Ester, M. MOLI: multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics 35, i501–i509 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Yang, J., Li, A., Li, Y., Guo, X. & Wang, M. A novel approach for drug response prediction in cancer cell lines via network representation learning. Bioinformatics 35, 1527–1535 (2019).

CAS  PubMed  Google Scholar 

Balasubramaniam, S. et al. FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin. Cancer Res. 23, 7165–7170 (2017).

CAS  PubMed  Google Scholar 

Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the australian ovarian cancer study group. J. Clin. Oncol. 30, 2654–2663 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Braicu, C. et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers 11, E1618 (2019).

PubMed  Google Scholar 

Shin, M. H., Kim, J., Lim, S. A., Kim, J. & Lee, K.-M. Current insights into combination therapies with MAPK inhibitors and immune checkpoint blockade. Int. J. Mol. Sci. 21, E2531 (2020).

PubMed  Google Scholar 

Subramanian, J., Katta, A., Masood, A., Vudem, D. R. & Kancha, R. K. Emergence of ERBB2 mutation as a biomarker and an actionable target in solid cancers. Oncologist 24, e1303–e1314 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Cousin, S. et al. Targeting ERBB2 mutations in solid tumors: biological and clinical implications. J. Hematol. Oncol. 11, 86 (2018).

PubMed  PubMed Central  Google Scholar 

Zou, Z., Tao, T., Li, H. & Zhu, X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 10, 31 (2020).

PubMed  PubMed Central  Google Scholar 

Senkevitch, E. & Durum, S. The promise of Janus kinase inhibitors in the treatment of hematological malignancies. Cytokine 98, 33–41 (2017).

CAS  PubMed  Google Scholar 

Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965–1977 (2014).

CAS  PubMed  Google Scholar 

Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271–1285 (2015).

CAS  PubMed  PubMed Central  Google Scholar